A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Darolutamide (Primary) ; Enzalutamide (Primary)
- Indications Bladder cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer
- Focus Pharmacodynamics
- Sponsors Bayer
- 05 Nov 2019 Planned End Date changed from 22 Oct 2019 to 5 Nov 2019.
- 20 Aug 2019 Planned End Date changed from 15 Oct 2019 to 22 Oct 2019.
- 20 Aug 2019 Planned primary completion date changed from 10 Sep 2019 to 24 Sep 2019.